Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Bridging neuro-biomarkers and MR imaging: The synergistic role of glial fibrillary acidic protein in early CNS disease diagnosis

Ghaderian M., Shahbazi-Gahrouei D., Nikzad S., Didehban E., Hafezi H., Laher I.

Narrative Review on Neuroinflammation, published in IBRO Neurosci Rep (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
IBRO Neurosci Rep (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40487594
PMCID
PMC12141570
DOI
10.1016/j.ibneur.2025.04.016
Citations
1

Abstract (original English)

Molecular neuroimaging is a powerful and emerging tool for the early detection and monitoring of central nervous system (CNS)-related and neurodegenerative diseases. Biomarkers play a crucial role in diagnostic accuracy, prognosis, and treatment efficacy. Among these, Glial Fibrillary Acidic Protein (GFAP), a cytoskeletal intermediate filament protein, serves as a key indicator of astrocytic activation and neuroaxonal injury. Elevated levels of GFAP in cerebrospinal fluid (CSF) and blood-based samples (serum/plasma) are increasingly recognized as potential biomarkers for neurodegeneration and CNS pathology. Advanced molecular imaging techniques, including Diffusion Tensor Imaging (DTI) and Diffusion-Weighted Imaging (DWI), along with conventional magnetic resonance imaging (MRI), provide visual scoring, local morphometry, and volumetric analysis. Therefore, integrating GFAP with neuroimaging modalities offers the potential to improve disease characterization, allowing for accurate spatial mapping of neurodegeneration and monitoring of disease progression at a molecular level. The relationship between MRI and GFAP is currently under evaluation. This review explores the interplay between GFAP and molecular neuroimaging, highlighting their combined potential to enhance early diagnosis, prognosis, and treatment monitoring of CNS disorders.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research